Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

BMC Nephrology

Research

Wenhan Bao¹  Yue Wang¹  Danxia Zheng¹  Song Wang¹  Sijia Zhou¹  Zhenling Deng¹  Zhuan Cui¹ 

[1] Department of Nephrology, Peking University Third Hospital, No. 49 North Garden Road, 100191, Beijing, China;

关键词: Anti-phospholipase A2 receptor antibody;    Membranous nephropathy;    Nephrotic syndrome;    Rituximab;    Mini-dose;   

DOI  :  10.1186/s12882-023-03206-1

 received in 2022-11-22, accepted in 2023-05-18,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe currently recommended dose of rituximab for primary membranous nephropathy is as high as that for lymphoma. However, the clinical manifestations of membranous nephropathy vary widely. Therefore, achieving individualized treatment is a topic that needs to be explored. This study assessed the efficacy of monthly mini-dose rituximab monotherapy in patients with primary membranous nephropathy.MethodsThis retrospective study included 32 patients with primary membranous nephropathy treated at Peking University Third Hospital between March 2019 and January 2023. All patients were anti-phospholipase A2 receptor (PLA2R) antibody-positive and received rituximab 100 mg intravenously monthly for at least 3 months without other immunosuppressive therapy. Rituximab infusions were sustained until either remission of the nephrotic syndrome or a minimum serum anti-PLA2R titer ˂ 2 RU/mL was achieved.ResultsThe baseline parameters included: proteinuria, 8.5 ± 3.6 g/day; serum albumin, 24.8 ± 3.4 g/L; and anti-PLA2R antibody, 160 (20–2659) RU/mL. B-cell depletion was achieved in 87.5% patients after the first dose of rituximab 100 mg and in 100% after the second equivalent dose. The median follow-up was 24 months (range 18–38). Twenty-seven (84%) patients achieved remission, with 11 (34%) patients achieving complete remission by last follow-up. The relapse-free survival from the last infusion was 13.5 months (range 3–27). Patients were stratified into the low-titer (< 150 RU/mL, n = 17) and high-titer groups (≥ 150 RU/mL, n = 15) based on the anti-PLA2R titer. Sex, age, urinary proteins, serum albumin, and estimated glomerular filtration rate at baseline did not differ significantly between the two groups. At 18 months, compared to the low-titer group, the rituximab dose (960 ± 387 vs 694 ± 270 mg, p = 0.030) was higher, while serum albumin (37.0 ± 5.4 vs 41.3 ± 5.4 g/L, p = 0.033) and the complete remission rate (13% vs 53%, p = 0.000) were both lower in the high-titer group.ConclusionsMonthly rituximab 100 mg appeared as a potential effective regimen for treating anti-PLA2R-associated primary membranous nephropathy with a low anti-PLA2R titer. The lower the anti-PLA2R titer, the lower the rituximab dose required to achieve remission.Trial registrationA retrospective study, registered at ChiCTR (ChiCTR2200057381) on March 10, 2022.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq789.gif

41116_2023_36_Article_IEq777.gif

41116_2023_36_Article_IEq753.gif